Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCSF.

Prospective Isolation Of Tumor-Reactive Cytotoxic Cd4+ T Cells For Bladder Cancer Therapy

UCSF researchers have discovered a method for the isolation and expansion ex vivo of an endogenous population of bladder tumor-reactive cytotoxic CD4+ T cells that can be used to specifically and potently treat bladder cancer.

Engineered High Affinity Antibodies for Detection of Phosphotyrosine Proteins

This invention comprises high affinity phosphotyrosine antibodies with greater thermal stability and detection capability for Western Blotting and Immunofluorescence compared to popular commercial antibodies.

Modulating IRE1a/ß Kinase for Treatment of Unfolded Protein Response (UPR)-related Diseases

This invention identifies a series of compounds which can selectively regulate the kinase activity of IRE1α and IRE1β, which are paralogous enzymes critical for the activation of the unfolded protein response (UPR) and that may have implications in cell-degenerative diseases such as diabetes, cancer, fibrosis, asthma, and retinitis pigmentosa.  

First-in-class Targeted Therapy for Acute Kidney Injury (AKI)

This invention provides the first-in-class targeted therapy for acute kidney injury (AKI) by systemically administering protein WFDC2.

Lipid-Modified Oligonucleotides For Sample Barcoding in Droplet Microfluidics-Based Single-Cell RNA Sequencing

A new strategy for barcoding single living cells using lipid-modified oligonucleotides that can vastly enhance sample multiplexing in droplet microfluidics-based RNA sequencing

Small Molecule Pendrin Inhibitors for Treatment of Inflammatory Airway Diseases and Diuretic Resistance

Small molecule pendrin inhibitors for treating inflammatory lung diseases.

Novel Small Molecule Drug for the Treatment of Constipation and Oxalate Kidney Stones

UCSF researchers have developed a novel small molecule drug that specifically targets and inhibits SLC26A3 (DRA), an anion exchanger whose inhibition is expected to have therapeutic benefit in constipation and oxalate kidney stone disease.

“EchoCV”: A Web-Based Fully Automated Echocardiogram Interpretation System

Echo-CV is a novel, fully-automated system for analyzing images obtained from an echocardiogram that can be deployed on the web.